Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 10 clinical trials
A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder

The objective of this study is to evaluate the safety and efficacy of eculizumab in pediatric participants (aged 2 to < 18 years) with relapsing neuromyelitis optica spectrum disorder

immunosuppressive therapy
immunosuppressive agents
human chorionic gonadotropin
aquaporin 4
  • 24 Feb, 2021
  • 29 locations
Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)

The main objective of this study is to evaluate the efficacy of danicopan as add-on therapy to a complement component 5 (C5) inhibitor (eculizumab or ravulizumab) in participants with PNH who

  • 09 Mar, 2021
  • 17 locations
Proof of Concept Study of ACH-0145228 in Paroxysmal Nocturnal Hemoglobinuria (PNH)

The study will evaluate the efficacy and safety of the oral Factor D (FD) inhibitor ALXN2050 (ACH-0145228) monotherapy in treatment nave patients, patients currently treated with eculizumab who

complement c5
platelet count
neutrophil count
  • 05 May, 2021
  • 8 locations
A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of eculizumab in the treatment of pediatric refractory gMG based on change from Baseline in

serologic test
anticholinesterase agents
immunosuppressive agents
generalized myasthenia gravis
  • 25 Jan, 2021
  • 14 locations
Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients

mortality. The investigators hypothesize that early intervention with complement blocker eculizumab will double survival in HCT recipients with high risk TMA, as compared to historical untreated controls

organ dysfunction syndrome
stem cell transplantation
renal replacement
replacement therapy
  • 24 Jan, 2021
  • 3 locations
Therapeutic Orientation Test in Thrombotic Microangiopathy

Haemolytic and Uraemic Syndrome (HUS) is a serious disease requiring rapid diagnosis and management. The atypical HUS diagnosis has been greatly improved by anti-CS antibody (Eculizumab) wich

  • 22 Apr, 2021
  • 1 location
Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)

active disease at baseline and those with inactive disease on eculizumab, switching to pozelimab) at time points until 104 weeks To determine the effects of pozelimab on albumin and other serum

  • 26 Jan, 2021
  • 2 locations
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.

  • 25 Jan, 2021
  • 124 locations
Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria

This is prospective observational study of long-term pathogenic treatment of Elizaria in patients with paroxysmal nocturnal hemoglobinuria.

  • 29 Jan, 2021
  • 8 locations
An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMR

The aim of this trial is to collect data and provide a better understanding of the long-term outcome of imlifidase treatment on active or chronic active antibody-mediated rejection (AMR) in kidney transplant recipients. This is done by collecting data during an extended follow-up period of 3 years of clinical study …

  • 14 Feb, 2021
  • 3 locations